Skip to main content

Table 3 Compliance rates for KPIs for inpatient care of heart failure (n = 145)a

From: Compliance with clinical pathways for inpatient care in Chinese public hospitals

No

Key process indicators

No of Cases

Compliance rate (%)

1

Assessment of left ventricular function within 24 h of admission

133

77

2

Assessment of left ventricular function 1 week prior to discharge

121

1

3

Timely use of diuretics and potassium agents

140

96

4

Timely use of ACEI or ARBb

145

87

5

Use of β-blockers only for patients with CHFc

133

20

6

Use of aldosterone receptor blockers only for patients with severe health failured

142

85

7

Continued use of diuretics during hospitalization

145

93

8

Continued use of ACEI or ARB during hospitalization

144

87

9

Continued use of β-blocker during hospitalization

129

53

10

Continued use of aldosterone receptor blockers during hospitalization

139

84

11

Advised to use diuretics after discharge

139

82

12

Advised to use ACEI or ARB after discharge

140

76

13

Advised to use β-blocker after discharge

126

54

14

Advised to use aldosterone receptor blockers after discharge

134

78

15

Record of heart failure education

145

100

16

Assessment of cardiac function and living ability, and guidance activities after admission

145

100

17

Proper observation of patients (including symptoms, vital signs, water balance, weight, edema), provision of laboratory tests, and advice on diet and body-position after admission.

144

100

18

Assessment of tobacco and alcohol addiction after admission and Patient advised to quit smoking and to restrict alcohol consumption

145

54

19

Patient received psychological counseling

145

59

20

Patient advised on activity limitations after discharge

144

100

21

Patient received dietary and body-position guidance prior to discharge

143

100

22

Patient advised to quit smoking and to restrict alcohol consumption prior to discharge

143

99

 

Average

 

78

  1. aKPIs key process indicators
  2. bACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers
  3. cCHF chronic heart failure
  4. dSevere heart failure refers to the New York Heart Association (NYHA) cardiac function proposed test (NYHA functional) III, IV level of the patients